Bagherihagh Ali, Tajdini Ardavan, Ansari Reza, Moradi Behzad, Sadeghi Ivraghi Mehraveh, Heidari Farrokh
New Hearing Technologies Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Otorhinolaryngol. 2024;36(6):631-637. doi: 10.22038/ijorl.2024.74635.3510.
The main objective of this study is to examine the hypothesis that intratympanic corticosteroids can benefit the treatment of Bell's palsy and shorten the period needed for recovery.
This study was conducted prospectively using double-blind clinical trials. A total of 321 patients with acute unilateral facial paralysis were included in the survey, with 144 patients excluded due to exclusion criteria and 177 patients included. These patients were divided into an intervention group (54 patients) and a control group (123 patients). Prednisolone and acyclovir were given orally to both groups. Intratympanic dexamethasone was given to the intervention group as an additional treatment.
Patients' House-Brackmann (H.B.) scores were recorded when they were visited three days, one week, three weeks, three months, and six months after receiving intratympanic dexamethasone. It was discovered that there was no significant difference in H.B. scores between the intervention and control groups. The first day of symptom improvement in the intervention group was 1.81 days after starting treatment, while it took 2.91 days in the control group, which is a significant difference.
Intratympanic dexamethasone injection, in addition to the 10-day prednisolone-acyclovir therapy regimen, did not affect patients recovering from Bell's palsy in the short term (three weeks) or long term (six months) but is significantly effective in the first day of recovery as measured by the House-Brackmann scale.
本研究的主要目的是检验鼓室内注射皮质类固醇可有助于贝尔面瘫的治疗并缩短恢复所需时间这一假设。
本研究采用前瞻性双盲临床试验。共有321例急性单侧面瘫患者纳入调查,144例因排除标准被排除,177例被纳入。这些患者被分为干预组(54例)和对照组(123例)。两组均口服泼尼松龙和阿昔洛韦。干预组额外接受鼓室内注射地塞米松治疗。
在接受鼓室内注射地塞米松后3天、1周、3周、3个月和6个月复诊时记录患者的House - Brackmann(H.B.)评分。发现干预组和对照组的H.B.评分无显著差异。干预组症状改善的首日为开始治疗后1.81天,而对照组为2.91天,存在显著差异。
除了10天的泼尼松龙 - 阿昔洛韦治疗方案外,鼓室内注射地塞米松在短期(3周)或长期(6个月)内对贝尔面瘫恢复的患者无影响,但根据House - Brackmann量表测量,在恢复首日有显著疗效。